Key Events This Week
22 Jun: New 52-week high (Rs.153)
22 Jun: All-time high reached (Rs.153)
24 Jun: Golden Cross formation signalling bullish breakout
25 Jun: Week closes at Rs.126.05 (-1.18%)
Jul 08, 02:36 PM
BSE+NSE Vol: 8.57 k

Lotus Eye Hospital & Institute Ltd is rated Sell by MarketsMOJO. This rating was last updated on 05 Jun 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 30 June 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
22 Jun: New 52-week high (Rs.153)
22 Jun: All-time high reached (Rs.153)
24 Jun: Golden Cross formation signalling bullish breakout
25 Jun: Week closes at Rs.126.05 (-1.18%)

The 50-day moving average has crossed above the 200-day moving average for Lotus Eye Hospital & Institute Ltd, signalling a golden cross on 24 Jun 2026. While this technical event often suggests a shift towards bullish momentum, the broader technical and fundamental context must be examined to understand whether this signal stands on firm ground or is contradicted by other data.
Read full news article
Surging to a new 52-week high of Rs 153 on 22 Jun 2026, Lotus Eye Hospital & Institute Ltd has demonstrated remarkable price momentum, outperforming the Sensex by a wide margin over the past year. This milestone caps an 84.87% rally from its 52-week low of Rs 68, underscoring a sustained uptrend fuelled by a confluence of bullish technical indicators.
Read full news article
Lotus Eye Hospital & Institute Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Lotus Eye Hospital & Institute Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 5 June 2026, driven primarily by a marked improvement in technical indicators. Despite this upgrade, the company continues to face significant challenges in its financial performance and valuation metrics, reflecting a complex investment outlook for this micro-cap hospital sector stock.
Read full news article
25 May: Stock opens steady at Rs.107.05 with Sensex rallying 1.23%
26 May: Sharp stock gain of 3.69% to Rs.111.00 despite Sensex decline
27 May: Q4 FY26 results reveal profitability crisis; stock dips 1.62%
29 May: Downgrade to Strong Sell and quality deterioration weigh; stock closes at Rs.108.05 (-1.05%)

Lotus Eye Hospital & Institute Ltd has seen a marked shift in its valuation parameters, moving from a 'very expensive' to a 'risky' grade, driven by an extraordinary surge in its price-to-earnings ratio and other key multiples. This change signals a significant reassessment of the stock’s price attractiveness relative to its historical and peer benchmarks within the hospital sector.
Read full news articleLotus Eye Hospital and Institute Limiteds Eye Hospital and Institute Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Lotus Eye Hospital and Institute Limited has informed the Exchange regarding Board meeting held on November 14, 2019.
Lotus Eye Hospital and Institute Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 2019. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
No Upcoming Board Meetings
Lotus Eye Hospital & Institute Ltd has declared 5% dividend, ex-date: 18 Sep 23
No Splits history available
No Bonus history available
No Rights history available